This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1
Gene Therapy Open Access 25 January 2022
-
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Genome Medicine Open Access 27 June 2017
-
LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts
Scientific Reports Open Access 16 June 2017
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Spinal muscular atrophy approval boosts antisense drugs. Nat Biotechnol 35, 99–100 (2017). https://doi.org/10.1038/nbt0217-99
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0217-99
This article is cited by
-
Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1
Gene Therapy (2022)
-
An Evidence‐Based, Community‐Engaged Approach to Develop an Interactive Deliberation Tool for Pediatric Neuromuscular Trials
Journal of Genetic Counseling (2018)
-
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Genome Medicine (2017)
-
Biogen pays Forward in Tecfidera dispute
Nature Biotechnology (2017)
-
LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts
Scientific Reports (2017)